Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Ionis’s pancreatitis trial meets primary endpoint

Monday, March 6, 2017 7:01
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Ionis Pharmaceuticals Inc (NASDAQ:IONS) has announced positive results from a pivotal study on a drug designed to stave off acute pancreatitis.

The Phase 3 APPROACH study of the drug volanesorsen met its primary endpoint of reducing fat molecule (triglyceride) levels in patients with familial chylomicronemia syndrome (FCS), a condition that puts patients at risk of recurrent and potentially fatal pancreatitis.

The study found that triglyceride levels reduced on average by 77% after three months of treatment.

Patients with the highest documented frequency of pancreatitis attacks suffered no such attacks during the 52-week treatment period, Ionis revealed.

A reduction in abdominal pain was also observed by those on the volanesorsen treatment.

“We are excited about the strong profile of volanesorsen in not only robustly reducing triglycerides, but also providing additional important patient benefits. FCS is a life-threatening, rare disease with multiple severe daily and chronic manifestations. We believe the efficacy and safety data from volanesorsen studies demonstrate a favorable risk-benefit profile for patients with FCS,” said Paula Soteropoulos, president and chief executive officer, Akcea Therapeutics, a subsidiary of Ionis.

Dr Louis O’Dea, Akcea’s chief medical officer, said the success of the APPROACH study represented an important milestone towards the company’s first regulatory submissions for volanesorsen in the US, Canada and Europe in 2017.

“We seek to bring this new treatment as expeditiously as possible to FCS patients who have a high unmet need with potentially life-threatening consequences,” Dr O’Dea said.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/174315/ionis-s-pancreatitis-trial-meets-primary-endpoint-174315.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.